drugset / Trial / NCT00048373
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
Phase 2
Completed
20 enrolled
Baylor College of Medicine
The Methodist Hospital Research Institute · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies. We are also looking specifically at what side effects Enbrel has on patients. We expect to enroll 20 patients on this study and anticipate the subjects active participation to last up to one year.
Timeline
- Start
- 2001-10
- Primary completion
- —
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | — | Subcutaneous |